{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:58:28Z","timestamp":1773082708982,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.parkreldis.2008.12.007","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T10:11:59Z","timestamp":1232705519000},"page":"500-505","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors"],"prefix":"10.1016","volume":"15","author":[{"given":"Ripple","family":"Talati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Reinhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2008.12.007_bib1","unstructured":"Ernst ME. Parkinson's Disease. In: Dunsworth T, Richardson M, Cheng J, et al, eds. Pharmacotherapy Self-Assessment Program, 6th ed. Neurology and\u00a0Psychiatry. Lenexa, KS: American College of Clinical Pharmacy, 2007: 19\u201333"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): a report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Dersimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.parkreldis.2008.12.007_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jnnp.63.4.421","article-title":"Catechol-O-methyltransferase inhibition with tolcapone reduces the \u201cwearing-off\u201d phenomenon and levodopa requirements in fluctuating parkinsonian patients","volume":"63","author":"Baas","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.49.3.665","article-title":"Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment","volume":"49","author":"Waters","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00702-002-0799-z","article-title":"Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study","volume":"110","author":"Fenelon","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0404.2004.00363.x","article-title":"Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations","volume":"111","author":"Reichmann","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib10","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","article-title":"Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease","volume":"61","author":"Olanow","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuation patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study","volume":"74","author":"Brooks","year":"2003","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1017\/S0317167100052598","article-title":"Gait analysis in advanced Parkinson's disease-effect of levodopa and tolcapone","volume":"28","author":"Shan","year":"2001","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":". Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.parkreldis.2008.12.007_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","article-title":"Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa","volume":"23","author":"Rabey","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.parkreldis.2008.12.007_bib16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.20036","article-title":"Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study","volume":"19","author":"Waters","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/01.wnl.0000204007.46190.54","article-title":"Selegiline slows the progression of the symptoms of Parkinson disease","volume":"66","author":"Palhagen","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","article-title":"Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial","volume":"51","author":"Shoulson","year":"2002","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.parkreldis.2008.12.007_bib19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/mds.20914","article-title":"Minimal clinically important change on the unified Parkinson's disease rating scale","volume":"12","author":"Schrag","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.12.007_bib20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/mds.20913","article-title":"Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov Disord"},{"issue":"Suppl. 8","key":"10.1016\/j.parkreldis.2008.12.007_bib21","first-page":"42","article-title":"Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art","volume":"68","author":"Rapaport","year":"2007","journal-title":"J Clin Psychiatry"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802008003520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802008003520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T13:32:51Z","timestamp":1558099971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802008003520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1353802008003520"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2008.12.007","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}